v3.25.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Cash flows from operating activities:              
Net loss $ (3,704,438) $ (3,809,700) $ (2,694,362) $ (1,399,213) $ (7,514,138) $ (4,093,575)  
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:              
Stock based compensation         4,380,679 117,724  
Loss from change in fair value of common stock make-whole obligation         215,443  
Loss on sale of investments in equity securities         95,178  
Change in fair value of investment in equity securities 738,889   108,014   728,134 162,672  
Change in fair value of SAFE notes         955,000  
Loss on write-off of promissory notes and deposit         232,481  
Loss on write-off of deferred transaction cost         30,000  
Change in fair value of warrant liability         (2,171,692)    
Change in fair value of convertible notes   471,400   471,400  
Change in fair value of sponsor earnout shares         (528,000)    
Depreciation expense         1,536 505  
Changes in operating assets and liabilities:              
Prepaid expenses and other assets         239,723 (65,185)  
Accounts payable         128,902 266,068  
Accrued liabilities and other current liabilities         (328,696) 81,465  
Net cash used in operating activities         (4,490,450) (2,103,926)  
Cash flows from investing activities:              
Capital project costs         (2,278,760) (442,966)  
Land acquisition cost         (16,619)  
Proceeds from sale of investment in equity securities         78,311  
Investment in other long-term assets         (50,000)  
Purchase of property and equipment         (7,421)  
Net cash used in investing activities         (2,217,068) (500,387)  
Cash flows from financing activities:              
Proceeds from investor for issuance of SAFE notes         200,000  
Proceeds from issuance of common stock         122,551  
Proceeds from issuance of notes payable to related parties         250,000  
Repayment of notes payable to related parties         (250,000)  
Repayment of short-term loan from related parties         (2,000,000)  
Repayment of short-term loan         (1,808,552) (48,143)  
Proceeds from advance received from PIPE investors         125,000 75,002  
Deferred transaction costs paid         (25,000) (346,401)  
Proceeds from public offering         10,270,400  
Proceeds from warrant inducement exercises         2,971,040  
Transaction costs associated with public offering and warrant inducement         (1,252,152)  
Proceeds from issuance of convertible notes         2,100,000  
Repurchase of unvested shares         (1,593) (6,003)  
Net cash provided by financing activities         8,401,694 1,974,455  
Net (decrease)/ increase in cash         1,694,176 (629,858)  
Cash at the beginning of the period   $ 912,574   $ 1,271,824 912,574 1,271,824 $ 1,271,824
Cash at the end of the period $ 2,606,750   $ 641,966   2,606,750 641,966 $ 912,574
Supplemental disclosure for cash flow information:              
Interest paid         143,565 2,189  
Taxes paid         5,150  
Supplemental disclosure of non-cash investing and financing activities:              
Unpaid deferred transaction costs         1,612,331  
Unpaid capital project costs         1,698,517 27,253  
Reclass of advances to capital project costs         236,235  
Unpaid public offering issuance cost         623,345  
Unpaid warrant inducement issuance cost         29,000  
Incremental fair value of warrant inducement         2,108,480  
Issuance of common stock to short- term loan holders         6,200,000  
Issuance of common stock to PIPE investors         550,000  
Issuance of common stock to vendor         80,612  
Issuance of common stock under license arrangement         $ 343,000